Site Search
Professionals 733 results
Capabilities 89 results
Practice Area
Winston & Strawn’s private equity attorneys provide strategic advice and legal counsel to middle-market private equity funds, hedge funds, family offices, real estate funds, alternative asset managers, portfolio companies, and institutional investors. We have one of the broadest and most active national middle-market private equity practices in the U.S.
Practice Area
Our Patent Litigation Practice is one of the country’s most active and highly regarded. Our seasoned patent litigators bring extensive courtroom experience to every matter we handle. According to Lex Machina, we are among the top three national patent defense firms in the country for number of appearances and cases filed, and we also were the top national defense firm for number of patent trials in the last five years (2018–2022).
Industry
Experience 44 results
Experience
|July 17, 2025
D. Boral Capital Closes US$15M Robot Consulting IPO
Winston & Strawn LLP represented D. Boral Capital LLC and Craft Capital Management LLC in connection with the US$15M initial public offering of American Depositary Shares (ADSs) of Robot Consulting Co., Ltd. The offering consisted of 3,750,000 ADSs priced at $4.00 per ADS, and the company’s ADSs began trading on the Nasdaq Capital Market under the ticker symbol “LAWR” on July 17, 2025.
Experience
|May 27, 2025
PicoCELA Inc. Closes $1.8 Public Offering
Winston & Strawn represented Revere Securities LLC acted as the lead placement agent in connection with PicoCELA, Inc. in the closing of its public offering of 6,100,000 American Depositary Shares ("ADSs") at a public placement price of $0.30 per ADS. PicoCELA, Inc. received an aggregate gross proceeds of $1.83 million before deducting placement agent commission and other offering expenses. Each ADS represents one common share of the Company.
Experience
|April 11, 2025
Cuprina Holdings (Cayman) Limited Announces Closing of Initial Public Offering
Winston & Strawn is serving as underwriters counsel to R.F. Lafferty in connection with Cuprina Holdings, a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds as well as cosmeceuticals for the health and beauty sector, in its announced closing of $12,000,000 initial public offering. The Offering consists of 3,000,000 ordinary shares at a public offering price of $4 per share, for total gross proceeds of $12,000,000, before deducting underwriting discounts and offering expenses.
Insights & News 4,125 results
Webinar
|September 30, 2025
Tax Implications of the Big Beautiful Bill Act
Please join us for an engaging and informative webinar led by our experienced tax attorneys as they break down the most significant tax changes introduced by the recently enacted One Big Beautiful Bill Act of 2025, signed into law on July 4, 2025.
Seminar/CLE
|September 18, 2025
Winston Hosts New York Financial Services Symposium
Winston’s Financial Services Industry Group is pleased to host our inaugural Financial Services Symposium in our New York office on Thursday, September 18, 2025. This event will include a half-day of programming led by top industry thought leaders. Below you will find details about each panel.
Sponsorship
|September 18, 2025
Winston & Strawn Sponsors 21st Annual Boardroom Summit
Winston & Strawn is sponsoring the upcoming 21stAnnual Boardroom Summit & Board Committee Peer Exchange. This unique event will bring industry leading public company directors to discuss current trends, including shareholder activism, CEO succession strategies, and uses of AI in the boardroom.
Other Results 89 results
Site Content
In the product liability context, general causation is the legal and scientific determination of whether the product in question has the inherent capability to cause the alleged injury under certain circumstances. Establishment of general causation is a critical aspect of a plaintiff’s case, and typically requires scientific evidence, such as epidemiology or toxicology, and expert testimony to establish a causal connection between the product’s design, manufacturing, or warnings and the injury or injuries at issue. As contrasted to specific causation, the focus in a general causation inquiry is on whether the product or exposure, as a general matter, can cause the type of injury claimed by the plaintiff. A general causation inquiry does not assess any facts unique to a particular plaintiff.
Law Glossary
What Is the General Data Protection Regulation (GDPR) Law?
The European Union General Data Protection Regulation (GDPR) law is an act, applied across the Union, which directs data privacy. The GDPR law is designed to protect the data privacy of all EU citizens and guide organizational approaches to handling data, as well as transferring it across borders. Under the GDPR, breach notification is mandatory within 72 hours if the breach is likely to “result in a risk for the rights and freedoms of individuals.” The GDPR applies to organizations within the EU as well as those outside of the EU if they offer goods or services to European citizens. It also applies to organizations that monitor the behavior of data subjects online.